Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins

Blood Cancer J. 2021 Jun 4;11(6):108. doi: 10.1038/s41408-021-00499-z.

Franziska Blaeschke¹, Dana Stenger^{1

2}, Antonia Apfelbeck¹, Bruno L Cadilha³, Mohamed-Reda Benmebarek³, Jasmin Mahdawi¹, Eva Ortner¹, Mareike Lepenies¹, Nicola Habjan¹, Felicitas Rataj³, Semjon Willier¹, Theresa Kaeuferle^{1

4}, Robbie G Majzner^{5

6}, Dirk H Busch^{4

7

8}, Sebastian Kobold^{2

3}, Tobias Feuchtinger^{9

10

11}

¹ Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
² German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
³ Center for Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.
⁴ National Center for Infection Research (DZIF), Munich, Germany.
⁵ Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
⁶ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
⁷ Institute for Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany.
⁸ Focus Group "Clinical Cell Processing and Purification", Institute for Advanced Study, TUM, Munich, Germany.
⁹ Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany. tobias.feuchtinger@med.uni-muenchen.de.
¹⁰ German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. tobias.feuchtinger@med.uni-muenchen.de.
¹¹ National Center for Infection Research (DZIF), Munich, Germany. tobias.feuchtinger@med.uni-muenchen.de.

No abstract available

Publication types